Unknown

Dataset Information

0

The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children.


ABSTRACT: BACKGROUND:The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians. METHODS:Data for grass-allergic Canadians in three randomized, placebo-controlled, double-blind trials were analyzed post hoc: 1) adults ?18 y, grass-pollen season [GPS] 2009; 2) children 5-?<18 y, 2009; and 3) adults 18-65 y and children 5-?<18 y, GPS 2012. Data from the GPS 2009 trials were pooled to provide a more precise estimate of treatment effects than the individual studies would provide. In every trial, participants received once-daily grass SLIT-T or placebo approximately 12 weeks before and continuing throughout the GPS. Participants used daily electronic diaries to record AR/C symptoms and medication use for treatment of symptoms. The therapeutic effect of grass SLIT-T was measured as a total combined score (TCS?=?daily symptom score?+?daily medication score) averaged over the entire GPS. Safety was assessed by monitoring adverse events (AEs). RESULTS:In the three trials, 386 Canadian participants were randomized; the overall population had 2284 participants. Canadian participants treated with grass SLIT-T in the pooled adult-pediatric 2009 trials showed a 38% mean TCS reduction relative to placebo (-2.06 difference [95% CI: -3.72, -0.39]; 3.32 vs. 5.37). Participants treated with grass SLIT-T in the adult-pediatric 2012 trial showed a 37% median TCS reduction relative to placebo (-1.53 difference [95% CI: -2.1, -0.3]; 2.58 vs. 4.11). Similar efficacy findings were observed over the peak GPS. Approximately 90% of treatment-related AEs were mild or moderate in severity. Two Canadian participants had moderate systemic allergic reactions (skin, respiratory, abdominal symptoms) to grass SLIT-T; symptoms resolved within 1 hour without medical intervention or treatment. No serious or life-threatening treatment-related AEs occurred. CONCLUSION:The 2800 BAU Timothy grass SLIT-T significantly improved AR/C induced by Timothy grass pollen in adults and children ?5 y in Canadians, which was consistent with the robust efficacy observed in the overall trial population. The treatment was generally well tolerated. TRIAL REGISTRATION:Clinicaltrials.gov identifiers NCT00562159, NCT00550550, NCT01385371.

SUBMITTER: Hebert J 

PROVIDER: S-EPMC4326370 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children.

Hébert Jacques J   Blaiss Michael M   Waserman Susan S   Kim Harold H   Creticos Peter P   Maloney Jennifer J   Kaur Amarjot A   Li Ziliang Z   Nelson Harold H   Nolte Hendrik H  

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20141030 1


<h4>Background</h4>The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.<h4>Methods</h4>Data for grass-allergic Canadians in three randomized, placebo-controlled, double-blind trials were analyzed post hoc: 1) adults ≥18 y, grass-pollen season [GPS] 2009; 2) children 5  ...[more]

Similar Datasets

| S-EPMC4782305 | biostudies-other
| S-EPMC3437605 | biostudies-literature
| S-EPMC4363352 | biostudies-literature
| S-EPMC3689082 | biostudies-literature
| S-EPMC5049999 | biostudies-literature
| S-EPMC6494514 | biostudies-literature
| S-EPMC3983904 | biostudies-other
| S-EPMC4892109 | biostudies-other
| S-EPMC8656080 | biostudies-literature
| S-EPMC6343611 | biostudies-literature